Evidence map›Paper›PMID 38214136›Full record

ArticleCancer medicine2024

Erythrocyte PIG-A mutant frequencies in cancer patients receiving cisplatin.

Vasily N Dobrovolsky, Omar T Atiq, Robert H Heflich, Mackean Maisha, Page B McKinzie, Mason G Pearce, Timothy W Robison

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Vasily N DobrovolskyDivision of Genetic and Molecular Toxicology, National Center for Toxicological Research (NCTR), US Food and Drug Administration (FDA), Jefferson, Arkansas, USA.ORCID 0009-0001-6684-1334
Omar T AtiqUniversity of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas, USA.
Robert H HeflichDivision of Genetic and Molecular Toxicology, National Center for Toxicological Research (NCTR), US Food and Drug Administration (FDA), Jefferson, Arkansas, USA.
Mackean MaishaOffice of Scientific Coordination, NCTR, FDA, Jefferson, Arkansas, USA.
Page B McKinzieDivision of Genetic and Molecular Toxicology, National Center for Toxicological Research (NCTR), US Food and Drug Administration (FDA), Jefferson, Arkansas, USA.
Mason G PearceDivision of Genetic and Molecular Toxicology, National Center for Toxicological Research (NCTR), US Food and Drug Administration (FDA), Jefferson, Arkansas, USA.
Timothy W RobisonOffice of New Drugs, OII, DPTII, Center for Drug Evaluation and Research (CDER), US FDA, Silver Spring, Maryland, USA.
National Center for Toxicological Research · USUnited States Food and Drug Administration · USWinthrop Rockefeller Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCisplatin is a primary chemotherapy choice for various solid tumors. DNA damage caused by cisplatin results in apoptosis of tumor cells. Cisplatin-induced DNA damage, however, may also result in mutations in normal cells and the initiation of secondary malignancies. In the current study, we have used the erythrocyte PIG-A assay to evaluate mutagenesis in non-tumor hematopoietic tissue of cancer patients receiving cisplatin chemotherapy.

methodsTwenty-one head and neck cancer patients undergoing treatment with cisplatin were monitored for the presence of PIG-A mutant total erythrocytes and the young erythrocytes, reticulocytes (RETs), in peripheral blood for up to five and a half months from the initiation of the anti-neoplastic chemotherapy.

resultsPIG-A mutant frequency (MF) in RETs increased at least two-fold in 15 patients at some point of the monitoring, while the frequency of total mutant RBCs increased at least two-fold in 6 patients. A general trend for an increase in the frequency of mutant RETs and total mutant RBCs was observed in 19 and 18 patients, respectively. Only in one patient did both RET and total RBC PIG-A MFs did not increase at any time-point over the monitoring period.

conclusionCisplatin chemotherapy induces moderate increases in the frequency of  PIG-A mutant erythrocytes in head and neck cancer patients. Mutagenicity measured with the flow cytometric PIG-A assay may serve as a tool for predicting adverse outcomes of genotoxic antineoplastic therapy.

Indexed as

Head and Neck NeoplasmsNeoplasms, Second PrimaryCisplatinErythrocytesHumansMutagenesisCisplatinchemotherapyerythrocyteshead and neck cancer (HNC)mutationsPhosphatidylinositol glycan class-A (PIG-A) gene

Identifiers

PMID38214136
PMCPMC10905239
OpenAlexW4390795296

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.